Article Versions Notes

Stöth M, Müller-Diesing F, Mack P, Ackermann L, Metz C, Grunz J-P, Hackenberg S, Goncalves M, Gehrke T, Meyer TJ, et al. Blood-Based Inflammatory Markers Are Associated with Treatment Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Anti-PD-1 Therapy: CRP as a Superior Predictive Marker. International Journal of Molecular Sciences. 2025; 26(18):9154. https://doi.org/10.3390/ijms26189154

Stöth, Manuel, Flurin Müller-Diesing, Patricia Mack, Laura Ackermann, Corona Metz, Jan-Peter Grunz, Stephan Hackenberg, Miguel Goncalves, Thomas Gehrke, Till Jasper Meyer, and et al. 2025. "Blood-Based Inflammatory Markers Are Associated with Treatment Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Anti-PD-1 Therapy: CRP as a Superior Predictive Marker" International Journal of Molecular Sciences 26, no. 18: 9154. https://doi.org/10.3390/ijms26189154

Stöth, M., Müller-Diesing, F., Mack, P., Ackermann, L., Metz, C., Grunz, J.-P., Hackenberg, S., Goncalves, M., Gehrke, T., Meyer, T. J., & Scherzad, A. (2025). Blood-Based Inflammatory Markers Are Associated with Treatment Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Anti-PD-1 Therapy: CRP as a Superior Predictive Marker. International Journal of Molecular Sciences, 26(18), 9154. https://doi.org/10.3390/ijms26189154